ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

¸´·¢¼°ÄÑÖμ±ÐÔËèϸ°û°×Ѫ²¡²¡È˶àÒ©ÄÍÒ©»ùÒò¼ì²â¼°ÒâÒå_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ

·¢²¼Ê±¼ä£º2014-11-12 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
¡¾ÕªÒª¡¿ Ä¿µÄ Ñо¿¸´·¢¼°ÄÑÖμ±ÐÔËèϸ°û°×Ѫ²¡(AML)²¡È˶àÒ©ÄÍÒ©»ùÒò(mdr1)µÄ±í´ï¼°ÆäÓëÁÙ´²ÁÆЧµÄ¹Øϵ¡£·½·¨ ²ÉÓÃÄæת¼¾ÛºÏøÁ´·´Ó¦(RTPCR)¼ì²â65ÀýAML²¡ÈË(ÆäÖгõÕï×é38Àý£¬ÍêÈ«»º½â×é14Àý£¬¸´·¢ÄÑÖÎ×é13Àý)¡¢27Àý·Ç°×Ѫ²¡²¡È˺ͽ¡¿µÈË(°üÀ¨½¡¿µÈË15Àý¡¢È±ÌúÐÔƶѪ²¡ÈË10Àý¡¢ÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ°²¡ÈË2Àý)mdr1»ùÒòµÄ±í´ïˮƽ£¬²¢·ÖÎöÆäÁÙ´²ÒâÒå¡£½á¹û AML²¡ÈËmdr1»ùÒò±í´ïÑôÐÔÂʸßÓÚ¶ÔÕÕ×飬¸´·¢ÄÑÖÎ×émdr1»ùÒò±í´ïÑôÐÔÂʸßÓÚ³õÕï×éºÍÍêÈ«»º½â×飬ÁÙ´²ÄÍÒ©×émdr1»ùÒò±í´ïÑôÐÔÂÊÏÔÖø¸ßÓÚ·ÇÁÙ´²ÄÍÒ©×飬CRÂÊ·ÇÁÙ´²ÄÍÒ©×éÏÔÖø¸ßÓÚÁÙ´²ÄÍÒ©×飬²îÒì¾ùÓÐÏÔÖøÐÔ(¦Ö2=8.334¡«49.630£¬P0.01)¡£½áÂÛ mdr1»ùÒòÑôÐÔ±í´ïÓëAML²¡ÈËÁÙ´²ÄÍÒ©ÃÜÇÐÏà¹Ø£¬ÊÇÓ°ÏìÔ¤ºóµÄÖØÒªÒòËØ£¬¿É×÷Ϊ¼ì²âÁÙ´²ÄÍÒ©ºÍÅжÏÔ¤ºóµÄÖ¸±êÖ®Ò»¡£ ¡¾¹Ø¼ü´Ê¡¿ °×Ѫ²¡ ËèÑù ¶àÒ©ÄÍÒ©Ïà¹Øµ°°×ÖÊÀà ¿¹Ò©ÐÔ Ö×Áö [ABSTRACT]ObjectiveTo study the expression of multidrug resistance gene (MDRG) and the curative effect in relapse or refractory acute myelogenous leukemia (AML).MethodsA semiquantitative reverse transcription polymerase chain reaction (RTPCR) was used to investigate the transcription levels of the human MDRG in 65 AML patients and 27 controls, and analyze the its clinical significance.ResultsMDRG expression was significantly higher in AML patients than in the controls, and higher in relapsed/refractory AML patients than in those newly diagnosed or in complete remission. The gene expression was significantly lower in nonresistant patients than in resistant ones. Complete remission (CR) rate of nonresistant patients was higher than resistant ones (¦Ö2=8.324-49.630£¬P0.01).ConclusionMDRG overexpression is significantly associated with clinical multidrug resistance and prognosis, and it is one of the indicators for predicting the prognosis of AML. [KEY WORDS]leukemia, myeloid; multidrug resistanceassociated proteinsmdr1; drug resistance, neoplasm ¹úÄÚÍâÑо¿Ö¤Ã÷£¬¶àÒ©ÄÍÒ©»ùÒò(mdr1)µÄ´æÔÚ¼°±í´ïÊDzúÉú¶àÒ©ÄÍÒ©(MDR)µÄÖ÷Òª»úÖÆ¡£±¾ÎÄÓ¦ÓÃÄæת¼¾ÛºÏøÁ´·´Ó¦(RTPCR)¼¼Êõ¼ì²âÁË65Àý¼±ÐÔËèϸ°û°×Ѫ²¡(AML)²¡ÈË¡¢27Àý·Ç°×Ѫ²¡²¡È˺ͽ¡¿µÈ˵Ämdr1»ùÒò±í´ïˮƽ£¬·ÖÎömdr1»ùÒò±í´ïˮƽÓëÁÙ´²ÄÍÒ©µÄ¹Øϵ¡£ 1 ²ÄÁϺͷ½·¨ 1.1 ϸ°ûϵÓëϸ°ûÅàÑø K562/A02ÓÉÖйúҽѧ¿ÆѧԺѪҺѧÑо¿Ëù»ÝÔù£¬Óð¢Ã¹ËØ(ADM)ÓÕµ¼K562ϸ°û½¨Á¢µÄ¶àÒ©ÄÍҩϸ°ûÖê[1]£¬¾ßÓеäÐ͵ÄMDR±íÐÍ¡£K562/A02ϸ°ûÔÚÅàÑø¹ý³ÌÖмÓ1 ng/LµÄ°¢Ã¹ËØ£¬Ê¹ÓÃÇ°3 d³·Ò©¡£ 1.2 ²¡È˼°·Ö×é ¸ù¾Ý°×Ѫ²¡Õï¶Ï±ê×¼[2]£¬Ñ¡Ôñ¼±ÐÔËèϸ°û°×Ѫ²¡(AML)²¡ÈË65Àý£¬ÄÐ39Àý(ÄêÁä18¡«63Ëê)£¬Å®26Àý(ÄêÁä22¡«59Ëê)£¬ÖÐλÄêÁä34.2Ëê¡£ÆäÖгõÕï×é(AMLP)38Àý£¬ÍêÈ«»º½â(CR)×é(AMLC)14Àý£¬¸´·¢ÄÑÖÎ×é(AMLR)13Àý;M0ºÍM1¸÷1 Àý£¬M219Àý£¬M315 Àý£¬M414 Àý£¬M59Àý£¬M62Àý£¬M71Àý£¬ÔÓºÏÐÍ°×Ѫ²¡(HAL)3Àý¡£¶ÔÕÕ×é27Àý£¬ÆäÖÐÄÐ16Àý(ÄêÁä19¡«52Ëê)£¬Å®11Àý(ÄêÁä15¡«46Ëê)£¬ÖÐλÄêÁä30.9Ë꣬°üÀ¨½¡¿µÈË15Àý¡¢È±ÌúÐÔƶѪ²¡ÈË10Àý¡¢ÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ°²¡ÈË2Àý¡£15Àý½¡¿µÈËÈ¡ÍâÖÜѪ£¬Óà¾ùÈ¡¹ÇËè¡£²¡ÈËΪÇൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¼°ÁijÇÊÐÈËÃñҽԺסԺ²¡ÈË¡£ ÁÙ´²ÄÍÒ©Õï¶Ï±ê×¼£º¢Ù¶ÔÒ»Ïß·½°¸ÓÕµ¼ÖÎÁÆ2¸öÁƳÌÎÞЧ;¢ÚµÚ1´Î»º½âºó6¸öÔÂÄÚ¸´·¢;¢ÛµÚ1´Î»º½âºó6¸öÔÂÒÔÉϸ´·¢¾­ÓÕµ¼ÖÎÁÆÎÞЧ;¢Ü2´Î»ò2´ÎÒÔÉϸ´·¢¡£ 1.3 °ë¶¨Á¿RTPCR ϸ°û×ÜRNAµÄÌáÈ¡£ºÓÃTRIzolÌáȡϸ°û×ÜRNA¡£¾­MMLVÄæת¼øºÏ³ÉcDNA£¬ÒÔÄæת¼²úÎï¼ÓdNTPs¡¢PCR Buffer¡¢mdr1ÒýÎï½øÐÐPCR£¬È¡PCR²úÎﶨÁ¿10 ¦ÌL À©Ôö²úÎ25 g/LÇíÖ¬ÌÇÄý½ºµçÓ¾£¬¹à½ºÇ°¼ÓEB(1 mL 1¡ÁTAE ¼Ó1 ¦ÌL EB)£¬75 V£¬30¡«60 min£¬×ÏÍâÏßµÆϹ۲첢ÕÕÏ࣬ÓÃKodak Digital Science 1D Image Analysis Software¼°GD1Êý×Ö»¯Äý½º³ÉÏñ·ÖÎöÒÇɨÃ裬¼ÆËãmdr1»ùÒòÓë¦ÂactinµÄ±ÈÖµ¡£ 1.4 ͳ¼Æѧ´¦Àí Ó¦ÓÃҽѧͳ¼ÆѧÈí¼þSPSS 12.0´¦Àí£¬½á¹ûÓáÀs±íʾ£¬Êý¾Ý¼ä±È½ÏÓÃF¼ìÑé¼°¦Ö2¼ìÑé¡£ 2 ½á ¹û 2.1 AML²¡ÈËmdr1»ùÒòµÄ±í´ï AMLP×é¡¢AMLC×é¡¢AMLR×éºÍ¶ÔÕÕ×émdr1»ùÒò±í´ïÖµ·Ö±ðΪ0.78¡À0.76¡¢0.54¡À0.45¡¢1.64¡À1.75¡¢0.20¡À0.13£¬AML²¡ÈËmdr1»ùÒò±í´ïÖµ¸ßÓÚ¶ÔÕÕ×飬ÇÒAMLR×é¸ßÓÚAMLP×é¡¢AMLC×飬²îÒìÓÐÏÔÖøÐÔ(P0.001)¡£¼ûͼ1¡£ ͼ1 mdr1»ùÒò±í´ïµÄRTPCR¼ì²â ¢ÙMarker;¢ÚAMLP;¢ÛAMLR;¢ÜAMLC;¢ÝAMLM5;¢ÞNormal;¢ßK562/A02;¢àK562 ¸ù¾Ý¶ÔÕÕ×éºÍAML¸÷×émdr1»ùÒòÔÚ²»Í¬×é±ðµÄ±í´ï£¬½«mdr1/¦ÂactinµÄ±ÈÖµ¡Ý1.0¶¨Îªmdr1»ùÒòÑôÐÔ±í´ï£¬¶ÔÕÕ×émdr1Óë¦Âactin±ÈÖµ¾ù0.1£¬¸ù¾Ý´Ë±ê×¼£¬AMLR×émdr1»ùÒòÑôÐÔ±í´ïÂÊÏÔÖø¸ßÓÚAMLP×éºÍAMLC×飬²îÒìÓÐÏÔÖøÐÔ(¦Ö2=9.578¡¢8.324£¬P0.05)¡£¼û±í1¡£±í1 ¸÷×éAML²¡ÈËmdr1»ùÒòÑôÐÔ±í´ï×é±ðnÑôÐÔÀýÊýÑôÐÔÂÊAML²¡ÈËÁÙ´²ÄÍÒ©×émdr1»ùÒòÑôÐÔ±í´ïÂÊÏÔÖø¸ßÓÚ·ÇÁÙ´²ÄÍÒ©×飬²îÒìÓÐÏÔÖøÐÔ(¦Ö2=32.42£¬P0.01)£¬CRÂÊ·ÇÁÙ´²ÄÍÒ©×éÏÔÖø¸ßÓÚÁÙ´²ÄÍÒ©×飬²îÒìÓÐÏÔÖøÐÔ(¦Ö2=49.63£¬P0.01)¡£¼û±í2¡£ ±í2 AML²¡ÈËmdr1»ùÒò±í´ïÓëÁÙ´²ÄÍÒ©µÄ¹Øϵ×é ±ðnmdr1ÑôÐÔ(Àý)±í´ïÂÊ(¦Ö%)CR(Àý)CRÂÊ(¦Ö%)ÁÙ´²ÄÍÒ©251768.0416.0·ÇÁÙ´²ÄÍÒ©40410.03895.0 ¡¾ÂÛÎÄÕªÒª¡¿¡¶Ó¢Óï¿Î³Ì±ê×¼¡·¹ØÓÚ½ÌѧÖÐӦעÒâµÄÎÊÌⲿ·ÖÖ¸³ö:ÔÚ½Ìѧ¹ý³ÌÖÐ,ҪʼÖÕÌåÏÖѧÉúµÄÖ÷ÌåµØλ,½ÌʦӦ³ä·Ö·¢»ÓѧÉúÔÚѧϰ¹ý³ÌÖеÄÖ÷¶¯ÐԺͻý¼«ÐÔ,¼¤·¢Ñ§ÉúµÄѧϰÐËȤ,ÓªÔì¿íËÉ¡¢ºÍгµÄѧϰÆø·Õ¡£ ¡¾ÂÛÎĹؼü´Ê¡¿Ó¢Óï½Ìѧ;¿ÎÌÃ;ЧÂÊ ½Ìѧʵ¼ùÖ¤Ã÷,ͬÑùµÄ¿ÎÎÄ,ͬÑùµÄ½ÌѧÄÚÈÝ,ͬÑùˮƽµÄѧÉú,ÓÉÓÚ½Ìѧ·½·¨²»Í¬,½ÌѧЧ¹ûÍùÍù´ó²»Ò»Ñù¡£Òò´Ë,Ñо¿ÈçºÎÔËÓø÷ÖÖ½ÌѧҪËØ,°´ÕÕ×î¼ÑµÄ·½Ê½×éÖ¯½Ì²Ä,Ìá¸ß¿ÎÌýÌѧЧÂÊ,ʹѧÉúÓ¢Óï½ÌѧÕæÕý×öµ½ÇḺµ£,µÍÏûºÄ,¸ßЧÂʾßÓÐÊ®·ÖÖØÒªÒâÒå¡£
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö